Cobrek Pharmaceuticals

Perrigo Announces FDA Final Approval Of Betamethasone Valerate FoamPerrigo Co. (Nasdaq: PRGO) Tuesday announced that its partner, Cobrek Pharmaceuticals Inc., received final approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for betamethasone valerate foam 0.12 percent, the generic equivalent of Luxiq Foam.
Best Winter Festivals In Metro Detroit
Thanksgiving Parade Guide

Watch & Listen